I De Lepeleire
Overview
Explore the profile of I De Lepeleire including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
567
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leaker B, Malkov V, Mogg R, Ruddy M, Nicholson G, Tan A, et al.
Mucosal Immunol
. 2016 Sep;
10(2):408-420.
PMID: 27677865
Non-invasive mucosal sampling (nasosorption and nasal curettage) was used following nasal allergen challenge with grass pollen in subjects with allergic rhinitis, in order to define the molecular basis of the...
2.
Zuiker R, Tribouley C, Diamant Z, Boot J, Cohen A, Van Dyck K, et al.
Eur Clin Respir J
. 2016 Jul;
3:31324.
PMID: 27421833
Background: Inhaled allergen challenge is a validated disease model of allergic asthma offering useful pharmacodynamic assessment of pharmacotherapeutic effects in a limited number of subjects. Objectives: To evaluate whether an...
3.
Depre M, MacLeod C, Palcza J, Behm M, De Lepeleire I, Han T, et al.
Cephalalgia
. 2013 Jun;
33(16):1292-301.
PMID: 23798725
Objective: The objective of this article is to assess the effects of sumatriptan monotherapy, telcagepant monotherapy, and their combination on blood pressure (BP) in migraine patients during a headache-free period....
4.
Van Laere K, de Hoon J, Bormans G, Koole M, Derdelinckx I, De Lepeleire I, et al.
Clin Pharmacol Ther
. 2012 Jun;
92(2):243-50.
PMID: 22739139
The type 1 neurokinin receptor (NK1R) antagonist aprepitant and its i.v. prodrug fosaprepitant have been approved for prevention of acute and delayed nausea and vomiting associated with chemotherapy. This study...
5.
Atack J, Hallett D, Tye S, Wafford K, Ryan C, Sanabria-Bohorquez S, et al.
J Psychopharmacol
. 2010 Feb;
25(3):329-44.
PMID: 20156926
In the accompanying paper we describe how MRK-409 unexpectedly produced sedation in man at relatively low levels of GABA(A) receptor occupancy (∼10%). Since it was not clear whether this sedation...
6.
Atack J, Wafford K, Street L, Dawson G, Tye S, Van Laere K, et al.
J Psychopharmacol
. 2010 Feb;
25(3):314-28.
PMID: 20147571
MRK-409 binds to α1-, α2-, α3- and α5-containing human recombinant GABA(A) receptors with comparable high affinity (0.21-0.40 nM). However, MRK-409 has greater agonist efficacy at the α3 compared with α1...
7.
Van der Schueren B, Rogiers A, Vanmolkot F, Van Hecken A, Depre M, Kane S, et al.
J Pharmacol Exp Ther
. 2008 Jan;
325(1):248-55.
PMID: 18216286
The purpose of this study was to identify the mediators involved in capsaicin-induced vasodilation in the human skin and to evaluate a pharmacodynamic model for the early clinical evaluation of...
8.
Lai E, Wenning L, Crumley T, De Lepeleire I, Liu F, de Hoon J, et al.
Clin Pharmacol Ther
. 2007 Sep;
83(6):840-7.
PMID: 17882161
Laropiprant is a selective antagonist of the prostaglandin D(2) (PGD(2)) receptor subtype 1 (DP1). Three double-blind, randomized, placebo-controlled studies evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple...
9.
Van der Schueren B, de Hoon J, Vanmolkot F, Van Hecken A, Depre M, Kane S, et al.
Br J Clin Pharmacol
. 2007 Jun;
64(5):580-90.
PMID: 17578484
Aims: Part I: to establish the dose and appropriate application site of capsaicin on the human forearm in order to produce a robust and reproducible dermal blood flow (DBF) response....
10.
Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1
Lai E, De Lepeleire I, Crumley T, Liu F, Wenning L, Michiels N, et al.
Clin Pharmacol Ther
. 2007 Mar;
81(6):849-57.
PMID: 17392721
Niacin (nicotinic acid) reduces cardiovascular events in patients with dyslipidemia. However, symptoms associated with niacin-induced vasodilation (e.g., flushing) have limited its use. Laropiprant is a selective antagonist of the prostaglandin...